Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation

Haematologica

Volumn 98, Issue 4, 2013, Pages 549-554

  Bloemen, Saartje ^a   Coenraad Hemker, H ^a   Al Dieri, Raed ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; DERMATAN SULFATE; HEPARIN; MELAGATRAN; OTAMIXABAN; PENTASACCHARIDE;

ARTICLE; BLOOD CLOTTING; DOSE RESPONSE; HUMAN; MALE; NORMAL HUMAN; PHARMACODYNAMICS; THROMBOCYTE POOR PLASMA;

ANTICOAGULANTS; ANTITHROMBIN III; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION TESTS; CYCLIC N-OXIDES; DERMATAN SULFATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HEPARIN; HUMANS; OLIGOSACCHARIDES; PYRIDINES; THROMBIN;

EID: 84875637036     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.073601     Document Type: Article

References (47)

1. Bauer KA. New anticoagulants: anti IIa vs anti Xa-is one better? J Thromb Thrombolysis. 2006;21(1):67-72.
2. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52.
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51.
5. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92.
6. Adams M. Assessment of thrombin generation: useful or hype? Semin Thromb Hemost. 2009;35(1):104-10.
7. Eerenberg ES, van Es J, Sijpkens MK, Büller HR, Kamphuisen PW. New anticoagulants: Moving on from scientific results to clinical implementation. Ann Med. 2011;43(8): 606-16.
8. Ho SJ, Brighton TA. Ximelagatran: direct thrombin inhibitor. Vasc Health Risk Manag. 2006;2(1):49-58.
9. Gomez-Outes A, Suarez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernández C, Vargas-Castrillón E. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis. 2011;5(1):33-59.
10. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285-95.
11. Petitou M, Casu B, Lindahl U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie. 2003;85(1-2):83-9.
12. Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem. 1983;258(11): 6713-6.
13. Boneu B, Necciari J, Cariou R, Sié P, Gabaig AM, Kieffer G, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost. 1995;74(6):1468-73.
14. Chu V, Brown K, Colussi D, Gao J, Bostwick J, Kasiewski C, et al. Pharmacological characterization of a novel factor Xa inhibitor, FXV673. Thromb Res. 2001;103(4):309-24.
15. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost. 1998;79(1):110-8.
16. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003; 33(1):4-15.
17. Hemker HC, Hemker PW, Al Dieri R. The technique of measuring thrombin generation with fluorescent substrates: 4. The Htransform, a mathematical procedure to obtain thrombin concentrations without external calibration. Thromb Haemost. 2009;101(1):171-7.
18. Béguin S, Wielders S, Lormeau JC, Hemker HC. The mode of action of CY216 and CY222 in plasma. Thromb Haemost. 1992; 67(1):33-41.
19. Paccaly A, Frick A, Rohatagi S, Liu J, Shukla U, Rosenburg R, et al. Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for phase 2/3 simulation of exposure. J Clin Pharmacol. 2006; 46(1):37-44.
20. Hacquard M, Perrin J, Lelievre N, Vigneron C, Lecompte T. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography. Thromb Res. 2011;127(1): 29-34.
21. Fuchs G. Mathematik für Mediziner und Biologen. Springer Verlag. 1969; 71.
22. Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. For. J Thromb Haemost. 2010;8(4):621-6.
23. Bounameaux H, Reber G. New oral antithrombotics: a need for laboratory monitoring. Against. J Thromb Haemost. 2010;8(4):627-30.
24. al Dieri R, Alban S, Béguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost. 2004;2(8):1395-401.
25. Beilfuss A, Grandoch M, Wenzel F, Hohlfeld T, Schrör K, Weber AA. Differential effects of factor IIa inhibitors on the endogenous thrombin potential. Ther Drug Monit. 2008;30(6):740-3.
26. Castoldi E, Rosing J. Thrombin generation tests. Thromb Res. 2011;127(Suppl 3):S21-5.
27. Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96(5):553-61.
28. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper-and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32(5-6):249-53.
29. van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol. 2008; 142(6):889-903.
30. Petros S, Siegemund T, Siegemund A, Engelmann L. The effect of different anticoagulants on thrombin generation. Blood Coagul Fibrinolysis. 2006;17(2):131-7.
31. Tripodi A, van den Besselaar A. Laboratory monitoring of anticoagulation: where do we stand? Semin Thromb Hemost. 2009; 35(1):34-41.
32. Erkens PM, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev. 2010:(9)CD001100.
33. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl): 204S-33S.
34. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA. 2006;296(4):397-402.
35. Al Dieri R, Peyvandi F, Santagostino E, Giansily M, Mannucci PM, Schved JF, et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost. 2002; 88(4):576-82.
36. Azar AJ, Koudstaal PJ, Wintzen AR, van Bergen PF, Jonker JJ, Deckers JW. Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction. Ann Neurol. 1996;39(3):301-7.
37. Hemker HC, Béguin S. Phenotyping the clotting system. Thromb Haemost. 2000; 84(5):747-51.
38. Butenas S, van't Veer C, Mann KG. "Normal" thrombin generation. Blood. 1999;94(7):2169-78.
39. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood. 1992;80(8):1998-2005.
40. Woodward M, Lowe GD, Rumley A, Tunstall-Pedoe H, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 1997;97(4):785-97.
41. Al Dieri R, Alban S, Béguin S, Hemker HC. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. J Thromb Haemost. 2006; 4(1):83-9.
42. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res. 2011;127(5): 457-65.
43. Jesty J, Lorenz A, Rodriguez J, Wun TC. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. Blood. 1996;87(6): 2301-7.
44. Hemker HC, Choay J, Beguin S. Free factor Xa is on the main pathway of thrombin generation in clotting plasma. Biochim Biophys Acta. 1989;992(3):409-11.
45. Herbert JM, Petitou M, Lormeau JC, Cariou R, Necciari J, Magnani HN, et al. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev. 1997;15(1):1-26.
46. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost. 2007;5(4):886-8.
47. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban-an oral direct factor Xa inhibitor. Thromb Haemost. 2010;103(4): 815-25.